HOMA-IR Score for PCOS: What It Means and Why There's No One Cutoff

If you already have your numbers in hand, use this quick check before reading further: find your fasting glucose and fasting insulin values on your lab report, confirm both were drawn from the same fasting blood sample, and note which insulin assay or reference range your lab lists — that detail matters more to interpreting the result correctly than the calculated number itself, for reasons this article explains in full below.

What Is a HOMA-IR Score, and How Is It Calculated?

HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is a number calculated from two values drawn from the same fasting blood sample — fasting glucose and fasting insulin — using the formula (fasting glucose in mmol/L × fasting insulin in µU/mL) ÷ 22.5. It was developed in a 1985 validation study that modeled the relationship between fasting glucose, fasting insulin, and beta-cell function, and it correlated with clamp-measured insulin resistance — the gold-standard direct measurement — at Rs = 0.88, a strong correlation at the population level.

The appeal is practical: a clamp study, the actual gold-standard test, requires hours of continuous glucose and insulin infusion in a research setting and is never used in routine clinical care. HOMA-IR needs a single fasting blood draw and a calculator, which is why it became one of the most widely used insulin-resistance markers in both research and everyday practice — a 2004 review by one of the index’s original authors noted it had already appeared in more than 500 publications by that point.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. The formula and the numbers below are unchanged by the rename; this article uses PCOS because that is still the term most readers search.

Why Is Insulin Resistance So Central to PCOS in the First Place?

Insulin sensitivity runs about 27% lower in women with PCOS than in women without it, independent of body weight, according to a meta-analysis of 28 gold-standard euglycemic-hyperinsulinemic clamp studies — the most accurate direct measurement available. A higher BMI worsened the resistance by a further 15%, but did not create it; the gap held in thinner participants too. That independence from body weight is exactly why HOMA-IR gets ordered even in lean PCOS presentations, where insulin resistance is less universal but still worth ruling in or out rather than assumed absent from appearance alone.

Why Isn’t There a Single HOMA-IR Cutoff for PCOS?

No HOMA-IR number applies universally across every lab, population, and insulin assay, because the number is built on an insulin measurement that isn’t standardized the way glucose is. The 2004 review of HOMA modeling states plainly that the raw insulin assay underlying the calculation varies enough between laboratories and manufacturers that a cutoff validated against one population, on one assay, does not transfer cleanly to another lab running a different assay on a different reference population. That is the direct, evidence-based reason you will see different HOMA-IR thresholds — commonly somewhere between 2.0 and 2.9 — cited as “the” cutoff for insulin resistance across different papers, calculators, and clinics: each was derived from its own reference population on its own assay, and none of them is more universally correct than the others.

What Does the 2023 Guideline Actually Say About HOMA-IR?

The 2023 international guideline states directly that clinically available insulin assays are of limited clinical relevance and are not recommended in routine PCOS care (Recommendations 1.9.12 and 3.1.10), pointing instead to a 2-hour, 75-gram oral glucose tolerance test (OGTT) for assessing glucose metabolism. Fasting insulin and HOMA-IR remain common in everyday clinical practice and can be genuinely useful for tracking an individual’s own trend over time, but a clinician who runs an OGTT rather than ordering fasting insulin is following the current guideline more closely, not skipping a step.

The Androgen Excess Society’s position statement recommends the 2-hour, 75-gram OGTT for every woman diagnosed with PCOS regardless of body mass index, with rescreening at least every two years if normal and annually if impaired glucose tolerance is found. A HOMA-IR calculation can be layered on top of that same blood draw if a fasting insulin is added to it, but the OGTT itself is the test both bodies name as the actual diagnostic priority for glucose metabolism in PCOS — HOMA-IR is a secondary, complementary number, not a replacement for it.

How Well Do Fasting Glucose and HbA1c Substitute for a Full Work-Up?

Poorly, which is a specific reason HOMA-IR alone is not enough either. A 2024 systematic review and meta-analysis of 2,628 women with PCOS tested HbA1c and fasting glucose against the OGTT as the reference standard and found HbA1c at the standard 6.5% cutoff had only 50% sensitivity for detecting type 2 diabetes in this population, meaning it missed half the women the OGTT identified. Fasting plasma glucose at 7.0 mmol/L performed only slightly better, at 58% sensitivity. Both were highly specific — they rarely flagged someone without diabetes — but that specificity does not help the person whose result comes back falsely reassuring. Since HOMA-IR is built from a fasting glucose and a fasting insulin, it inherits the same blind spot fasting glucose has on its own: PCOS-related glucose dysfunction often shows up only after a real glucose challenge, not at rest.

Where Your Phenotype Changes What a HOMA-IR Result Means

A high HOMA-IR is most expected, and does the most diagnostic work confirming an existing clinical picture, in the classic insulin-resistant phenotype — typically higher-androgen, irregular-cycle presentations where free testosterone tends to run ahead of total testosterone for the same low-SHBG reason. In this phenotype, an elevated HOMA-IR usually lines up with other signs already present rather than arriving as a surprise.

In the lean, hyperandrogenic phenotype, HOMA-IR is more often unremarkable, and a normal result here does not rule out PCOS or mean insulin plays no role at all — it means insulin resistance is not the dominant driver for that presentation specifically. The full mechanism connecting insulin resistance to PCOS, and what actually moves it in trials, covers the diet and metformin evidence for the phenotype where HOMA-IR runs high, including the specific trial numbers each approach moved. A lean, insulin-sensitive person can carry every Rotterdam diagnostic feature and still show an entirely unremarkable HOMA-IR — insulin resistance is common in PCOS, not universal, and the number describes one axis of the condition, not the whole diagnosis.

What Do the Individual Fasting Glucose and Insulin Numbers Mean Before They’re Combined?

A HOMA-IR calculation is only as informative as the two raw numbers that go into it, and reading those separately first is worth doing before jumping to the calculated ratio. A high fasting insulin next to a normal fasting glucose is the classic early PCOS pattern — it means the pancreas is producing extra insulin to hold blood sugar in the normal range, which is exactly the compensating mechanism HOMA-IR is trying to quantify. A normal fasting insulin next to a normal fasting glucose is more reassuring on this specific axis, though it does not rule out glucose problems that only appear after a real glucose load, which is the entire reason the OGTT exists as a separate, complementary test rather than a redundant one.

Fasting glucose on its own is the weaker half of the pair for catching PCOS-related insulin problems early, because the pancreas’s compensating extra insulin output is often exactly what keeps fasting glucose looking normal for years before any glucose abnormality becomes visible on a fasting draw. That is the direct, mechanistic reason a normal fasting glucose does not mean insulin resistance is absent — it may mean the compensation is still working, not that there’s nothing to compensate for.

How Does a HOMA-IR Result Fit Alongside the Rest of a Standard PCOS Panel?

HOMA-IR is one number among several typically drawn together, and its usefulness increases when read alongside the others rather than in isolation. Total and free testosterone, SHBG, and an androgen profile answer a different question — androgen excess — that sits on its own axis of the Rotterdam criteria, separate from insulin resistance entirely; how free and total testosterone get interpreted together is covered in its own dedicated breakdown. A lipid panel and blood pressure reading round out the metabolic picture the 2023 guideline recommends monitoring in PCOS generally, since insulin resistance, dyslipidemia and elevated blood pressure tend to cluster together in the same phenotype.

Reading HOMA-IR in isolation, disconnected from the rest of the panel, risks over-interpreting a single noisy number. Reading it alongside androgen levels, cycle history, and — where ordered — an OGTT gives a far more complete picture of which phenotype is actually present, and which levers (diet composition, metformin, or neither) have real trial evidence behind them for that specific presentation.

Your Next Step With a HOMA-IR Result

Ask which insulin assay your lab used and what reference range they apply to it, rather than comparing your number against a threshold pulled from an unrelated study or app. Then ask whether a 2-hour OGTT has also been done or ordered — the test most PCOS work-ups actually skip, and the one both the 2023 guideline and the Androgen Excess Society treat as the priority test for glucose metabolism, with HOMA-IR as a useful secondary number layered on top of it rather than a substitute for it. That full picture sits inside the broader PCOS blood-test panel and the wider diagnostic work-up overall, where a HOMA-IR result is one data point among several, not a stand-alone verdict.

Should You Track HOMA-IR Over Time, or Treat Each Result as Independent?

A single HOMA-IR result carries meaningful individual noise, but a trend across several results drawn under consistent conditions — fasting status, time of day, same lab and assay where possible — is more informative than any one value on its own, in the same way a single blood pressure reading matters less than a pattern across several visits. If diet changes, metformin, or another intervention has been started specifically to address insulin resistance, a repeat HOMA-IR several months later, drawn under the same conditions as the baseline, gives a genuine before-and- after comparison, even without a universal cutoff to compare either number against externally.

The caveat from earlier still applies to each individual measurement in that series: a same-person, different-day coefficient of variation around 31% means two draws taken a week apart, with nothing about the underlying physiology having changed, can show a meaningfully different number. That is a reason to weight a clear, sustained trend across several measurements more heavily than a single before-and-after pair, and to avoid reacting strongly to one result that moved in an unexpected direction without a second measurement to confirm the change is real rather than noise.

How This Fits With the Rest of a PCOS Diagnostic Journey

A HOMA-IR result usually arrives after PCOS has already been suspected or diagnosed through the Rotterdam criteria — irregular ovulation, signs of androgen excess, or polycystic ovarian morphology — rather than being part of the diagnostic criteria itself. Insulin resistance is not one of the three Rotterdam features, which is a genuinely common point of confusion: a person can meet every diagnostic criterion for PCOS with an entirely normal HOMA-IR, and a person without PCOS can have an elevated HOMA-IR from an unrelated cause such as prediabetes or obesity alone. The number describes a metabolic comorbidity that clusters with PCOS at a population level, not a requirement for the diagnosis.

That distinction matters for how a result should change what happens next. An elevated HOMA-IR alongside an existing PCOS diagnosis reasonably prompts a conversation about the diet and metformin evidence covered above, and about the OGTT if it has not already been done. An elevated HOMA-IR with no other PCOS features present is a metabolic finding worth discussing on its own terms — insulin resistance, prediabetes, or a related risk — rather than being treated as evidence toward a PCOS diagnosis it does not, on its own, support.

Who a Single HOMA-IR Number Cannot Reassure

Nobody, on its own. A normal HOMA-IR does not rule out PCOS-related glucose intolerance, since the same fasting-based blind spot that limits fasting glucose and HbA1c also limits HOMA-IR — all three miss problems that only appear after a real glucose challenge. And an elevated HOMA-IR does not, by itself, diagnose diabetes or prediabetes; it estimates insulin resistance, a related but distinct question, and the between-day variability described above means one elevated reading is not a reason to assume a stable, permanent finding without confirmation. Someone on metformin, insulin therapy, or — to a lesser extent — hormonal contraception at the time of the blood draw is also working with a number these formulas were not validated to interpret, since each of those directly alters glucose or insulin.